Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Theravance doses first patient in Phase II trial of ampreloxetine

Theravance aims to investigate the efficacy, safety and tolerability of ampreloxetine in a clinical trial. Credit: Photo by Thought Catalog on Unsplash.

  • Theravance Biopharma

Go Top